HIV/HBV/HCV (Early detection by PCR/NAAT)
Private HIV/HBV/HCV PCR/NAAT testing in London for £385, using molecular detection for earlier blood-borne virus assessment.
Turnaround time
3 business days
Biomarkers count
3
Book your test
Choose Service Type
Professional phlebotomist comes to you
+ £{{ home_visit_fee }}
Visit our clinic for your test
{{ clinic_visit_fee > 0 ? '+ £' + clinic_visit_fee : 'Free' }}
Home Visit Details
Home visits require at least 24 hours notice.
Select a clinic: Sorting by distance…
{{ clinicAddress(clinic) }}
{{ clinicAddress(selectedClinic) }}
Select a date
Select an hour
Available time slots: {{ timeSlots.length}}
Overview of the HIV/HBV/HCV (Early detection by PCR/NAAT) Test
The HIV/HBV/HCV (Early detection by PCR/NAAT) test is a specialist molecular blood-borne virus screen designed to detect viral genetic material rather than waiting for antibodies to develop.
The profile assesses molecular markers associated with HIV, Hepatitis B Virus and Hepatitis C Virus.
The laboratory profile includes HIV-1 and HIV-2 RNA, Hepatitis B Virus DNA and Hepatitis C Virus RNA.
PCR and other Nucleic Acid Amplification Tests detect viral RNA or DNA directly.
This allows molecular testing to identify infection earlier in the course of some blood-borne virus infections than conventional antibody-based testing.
The underlying laboratory profile is designed for use from approximately 10 days after a potential exposure, although the exact diagnostic interpretation depends on the virus, timing and clinical circumstances.
Early molecular testing should not be misunderstood as meaning that one test at one very early time point completely replaces standard follow-up serology.
The laboratory specifically uses this molecular profile in addition to appropriate HIV, HBV and HCV antigen or antibody testing where diagnostic confirmation is required.
For HIV, fourth-generation antibody/p24 antigen testing remains a standard component of routine diagnostic pathways.
For Hepatitis B, Surface Antigen and other serological markers provide different information about active infection, previous exposure and immunity.
For Hepatitis C, antibody testing indicates exposure while RNA testing identifies active viraemia.
This PCR/NAAT profile is therefore particularly useful where earlier detection after a relevant exposure is the clinical objective, but the full testing pathway should still consider follow-up serology.
What Does the HIV/HBV/HCV (Early detection by PCR/NAAT) Test Check?
The profile uses molecular amplification methods to look directly for viral nucleic acid associated with three important blood-borne viruses. This profile contains 3 principal viral targets.
HIV-1 and HIV-2 RNA
Detects HIV viral RNA using molecular amplification to support earlier investigation following a relevant exposure.
Hepatitis B Virus (HBV DNA)
Detects Hepatitis B viral DNA associated with active viral replication.
Hepatitis C Virus (HCV RNA)
Detects Hepatitis C viral RNA and therefore provides evidence of active viraemia.
Who May Benefit From the HIV/HBV/HCV (Early detection by PCR/NAAT) Test?
This profile may be useful after a significant recent blood or sexual exposure when earlier molecular detection of HIV, Hepatitis B and Hepatitis C is required.
People seeking earlier blood-borne virus testing after a recent exposure - PCR/NAAT can become informative before conventional antibody responses are fully established.
People following a significant needle or sharps exposure - HIV, HBV and HCV testing may form part of an occupational or clinical post-exposure pathway.
People following relevant blood-to-blood contact - Molecular testing can provide earlier information about active viral infection.
People following higher-risk sexual exposure - Early molecular testing may complement standard serological follow-up.
People whose clinician specifically recommends testing from around 10 days after exposure - The underlying laboratory profile is designed for this early-detection setting.
People requiring simultaneous early assessment of HIV, Hepatitis B and Hepatitis C - The profile examines all three viruses from one specialist pathway.
People with symptoms compatible with acute blood-borne viral infection after a relevant exposure - Molecular testing may provide useful early information.
People who understand that later serological follow-up may still be required - Early testing should form part of a complete testing pathway rather than replace it automatically.
How to Prepare
Do not delay urgent post-exposure treatment while waiting until day 10 to test.
Early molecular testing should be combined with the follow-up schedule advised by an appropriate sexual-health, infectious-disease or occupational-health clinician.
Symptoms and Reasons to Consider the HIV/HBV/HCV (Early detection by PCR/NAAT) Test
Early HIV, Hepatitis B and Hepatitis C infection can all be asymptomatic, and symptoms are too non-specific to determine which virus may be present.
No symptoms after a significant recent exposure - Absence of symptoms does not reliably exclude any of these viruses.
Flu-like illness following a relevant exposure - Acute HIV and acute viral hepatitis can produce non-specific systemic symptoms.
Fever and marked fatigue after a recent risk event - Molecular testing may be appropriate depending on timing.
Swollen lymph nodes after a possible HIV exposure - Primary HIV is one possible explanation among many.
Jaundice after a recent blood-borne virus exposure - Acute Hepatitis B or, less commonly, Hepatitis C can cause liver inflammation.
Dark urine or pale stools with jaundice - These symptoms require medical assessment for acute hepatitis.
A recognised needle or blood exposure - Testing may be appropriate even when no symptoms are present.
A sexual partner recently diagnosed with HIV, Hepatitis B or Hepatitis C - Prompt clinical advice can determine testing, vaccination or prophylaxis requirements.
If a potentially significant HIV exposure occurred within the previous 72 hours, seek urgent advice about HIV PEP.
Following Hepatitis B exposure, vaccination or Hepatitis B immunoglobulin may also be time-sensitive in selected situations.
Jaundice, severe systemic illness or symptoms of acute hepatitis require medical assessment rather than reliance on private screening alone.
How to Book Your HIV/HBV/HCV (Early detection by PCR/NAAT) Test
The HIV/HBV/HCV PCR/NAAT profile can be booked privately when early molecular testing after a recent exposure is required.
Choose the HIV/HBV/HCV (Early detection by PCR/NAAT)
Select the specialist early-detection blood-borne virus profile online.
Select your sample collection option
Choose an appropriate in-clinic or professional blood-collection pathway capable of meeting the molecular laboratory transport requirements.
Attend your appointment
A trained healthcare professional collects the required EDTA blood samples and records relevant exposure timing.
Laboratory analysis
Your samples undergo molecular amplification for HIV RNA, HBV DNA and HCV RNA.
Receive your results securely
Your authorised molecular results are delivered securely with additional confirmatory or serological follow-up advised where appropriate.
When Will I Receive My Results?
The expected laboratory turnaround for the HIV/HBV/HCV early PCR/NAAT profile is approximately 3 days after the required samples enter the laboratory system.
This is a specialist molecular virology profile involving several separate nucleic-acid targets.
The laboratory analyses HIV RNA, Hepatitis B DNA and Hepatitis C RNA and completes the required quality-control and authorisation procedures.
Samples must also meet the laboratory's collection and transport requirements.
The underlying laboratory specifies that samples should reach the laboratory within the required timeframe after collection.
If a molecular target is detected, confirmatory testing may be reflexed or further diagnostic investigation may be required, which can extend the final reporting process.
Understanding Your Results
A negative result means the relevant viral nucleic acid was not detected in the submitted specimen at the time of testing.
This is reassuring but must be interpreted according to the timing of exposure.
Testing extremely early can occur before viraemia has reached a detectable level.
The profile is therefore intended for early testing from around 10 days after exposure, with appropriate later serology still used according to the infection-specific pathway.
A detected HIV RNA result requires confirmatory HIV assessment.
A detected HBV DNA result indicates Hepatitis B viral genetic material and requires a full Hepatitis B clinical and serological evaluation.
A detected HCV RNA result indicates active Hepatitis C viraemia.
For all three viruses, molecular results should be interpreted with exposure history and complementary serological testing.
Early PCR/NAAT is not a substitute for every subsequent HIV, HBV or HCV follow-up test.
Why Book With London Blood Tests?
London Blood Tests provides private access to a specialist molecular profile designed for earlier detection of three major blood-borne viruses.
Molecular early-detection testing - Looks directly for viral RNA or DNA rather than relying solely on antibody development.
Three viruses assessed together - HIV, Hepatitis B and Hepatitis C are included.
Designed for early post-exposure testing - The underlying laboratory profile is intended for use from approximately 10 days after exposure.
Specialist PCR/NAAT technology - Uses nucleic-acid amplification methods.
Confidential testing - Results are delivered securely and privately.
Appropriate confirmatory pathways - Detected results can be followed with the required diagnostic investigations.
Specialist laboratory processing - Molecular samples are processed through a dedicated virology pathway.
Clear pricing - The HIV/HBV/HCV early PCR/NAAT profile costs £385.
Private HIV/HBV/HCV (Early detection by PCR/NAAT) Test in London
London Blood Tests provides private early molecular HIV, Hepatitis B and Hepatitis C testing for people requiring earlier assessment following a relevant exposure.
The profile costs £385.
The underlying laboratory turnaround is approximately 3 days after sample receipt.
PCR/NAAT provides valuable early information but should be used as part of a complete blood-borne virus testing pathway that includes appropriate serological follow-up.